Introduction
The world-wide Anticoagulants market is expected to garner USD 39 billion by 2026 and the market is expected to register CAGR growth over 7.9% during the next eight years.
Market Dynamics
Growing need for controlling the diseases such as kidney diseases and cardiovascular diseases is expected to propel the market growth over forecast period. In addition to this, rise in obesity patient and hence related disorders is another factor which is ultimately boosting the adoption of Anticoagulants in the healthcare areas and hence driving the market growth.
Market Insights
The worldwide anticoagulants market is anticipated to show significant growth during the forecast period, due to the increasing prevalence of cardiovascular disorders, venous thromboembolism (VTE), and others. Also, increasing adoption of novel oral anticoagulants (NOACs), and rising awareness of NOACs and it’s benefits in the emerging regions are boosting the market growth. The increasing obesity issues and rising population of elderly people, and rise in demand of novel therapeutics are some of the other factors driving the market growth. On the other hand, higher price of NOACs and lack of awareness about the anticoagulants to hamper the market growth.
The anticoagulant are drugs which functions as a blood thinners. The anticoagulants are used for preventing or reducing the coagulation of blood also used to prolong the blood clotting time. These drugs are majorly used for high risk of blood clots in various medical conditions. The importance of anticoagulants in preventing the clot formation in the human body is foreseen to be prime factor driving the market growth. Also, anticoagulants are used in the prevention of enlargement of the existing clots in the vein or arteries so that the health hazards are reduced to significant level.
Such properties of Anticoagulants are making them one of the irreplaceable part in the operational areas associated with the heart attack, stroke, deep venous thrombosis (DVT), pulmonary embolism (PE), angina, dialysis, atrial fibrillation (AF), thrombocytopenia, and myocardial infarction. In addition, anticoagulants plays an outstanding role while performing the surgery.
Market Segmentation
Market By Route of Administration
Market By Drug Class
- Factor XA Inhibitors (NOAC/DOAC)
- Heparins
- Direct Thrombin Inhibitors
- Vitamin K Antagonists
Market By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market By Indication
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Atrial Fibrillation
- Heart Attack
Market By Geography
- North America
- Europe
- UK
- Germany
- France
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- Rest of MEA
Regional Insights
In terms of consumption of anticoagulants, the North America was the dominant region in the year 2018 and the similar trend is expected to continue over forecast period due to rapid increase in the surgeries such as hip and knee surgeries in this region. Europe region is following the North America in terms of demand for anticoagulants. Increase in geriatric population is expected to be one of the key factor boosting the demand for anticoagulant in this region.
On the other hand, APAC region is expected to register significant CAGR growth rate over forecast period. The increasing health issues due to changing lifestyle as well as increasing surgical operations in this region are some of the prime factors accelerating the demand for anticoagulants in this region. Also, increasing network of healthcare facilities is expected to be another factor creating a demand for anticoagulants.
Market Participants
The key players operating in the global anticoagulants market are Bristol-Myers Squibb Company, Pfizer, Inc., Bayer Healthcare, Sanofi, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., and Daiichi Sankyo Company Limited.
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Anticoagulants
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Anticoagulants Market By Route of Administration
1.2.2.1. Global Anticoagulants Market Revenue and Growth Rate Comparison By Route of Administration (2015-2026)
1.2.2.2. Global Anticoagulants Market Revenue Share By Route of Administration in 2017
1.2.2.3. Oral
1.2.2.4. Injectable
1.2.3. Anticoagulants Market By Drug Class
1.2.3.1. Global Anticoagulants Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
1.2.3.2. Global Anticoagulants Market Revenue Share By Drug Class in 2017
1.2.3.3. Factor XA Inhibitors (NOAC/DOAC)
1.2.3.4. Heparins
1.2.3.5. Direct Thrombin Inhibitors
1.2.3.6. Vitamin K Antagonists
1.2.4. Anticoagulants Market By Distribution Channel
1.2.4.1. Global Anticoagulants Market Revenue and Growth Rate Comparison By Distribution Channel (2015-2026)
1.2.4.2. Global Anticoagulants Market Revenue Share By Distribution Channel in 2017
1.2.4.3. Hospital Pharmacies
1.2.4.4. Retail Pharmacies
1.2.4.5. Online Pharmacies
1.2.5. Anticoagulants Market By Indication
1.2.5.1. Global Anticoagulants Market Revenue and Growth Rate Comparison By Indication (2015-2026)
1.2.5.2. Global Anticoagulants Market Revenue Share By Indication in 2017
1.2.5.3. Deep Vein Thrombosis (DVT)
1.2.5.4. Pulmonary Embolism (PE)
1.2.5.5. Atrial Fibrillation
1.2.5.6. Heart Attack
1.2.6. Anticoagulants Market by Geography
1.2.6.1. Global Anticoagulants Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.6.2. North America Anticoagulants Market Revenue and Growth Rate (2015-2026)
1.2.6.3. Europe Anticoagulants Market Revenue and Growth Rate (2015-2026)
1.2.6.4. Asia-Pacific Anticoagulants Market Revenue and Growth Rate (2015-2026)
1.2.6.5. Latin America Anticoagulants Market Revenue and Growth Rate (2015-2026)
1.2.6.6. Middle East and Africa (MEA) Anticoagulants Market Revenue and Growth Rate (2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Anticoagulants Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Anticoagulants Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Anticoagulants Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Anticoagulants Major Manufacturers in 2017
CHAPTER 4. ANTICOAGULANTS MARKET BY ROUTE OF ADMINISTRATION
4.1. Global Anticoagulants Revenue By Route of Administration
4.2. Oral
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Injectable
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 5. ANTICOAGULANTS MARKET BY DRUG CLASS
5.1. Global Anticoagulants Revenue By Drug Class
5.2. Factor XA Inhibitors (NOAC/DOAC)
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Heparins
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Direct Thrombin Inhibitors
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Vitamin K Antagonists
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 6. ANTICOAGULANTS MARKET BY DISTRIBUTION CHANNEL
6.1. Global Anticoagulants Revenue By Distribution Channel
6.2. Hospital Pharmacies
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Retail Pharmacies
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Online Pharmacies
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 7. ANTICOAGULANTS MARKET BY INDICATION
7.1. Global Anticoagulants Revenue By Indication
7.2. Deep Vein Thrombosis (DVT)
7.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.3. Pulmonary Embolism (PE)
7.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.4. Atrial Fibrillation
7.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.5. Heart Attack
7.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 8. NORTH AMERICA ANTICOAGULANTS MARKET BY COUNTRY
8.1. North America Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. North America Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. U.S.
8.3.1. U.S. Anticoagulants Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.4. Canada
8.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.5. Mexico
8.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
CHAPTER 9. EUROPE ANTICOAGULANTS MARKET BY COUNTRY
9.1. Europe Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Europe Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. UK
9.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
9.4. Germany
9.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.5. France
9.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.6. Spain
9.6.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.7. Rest of Europe
9.7.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
CHAPTER 10. ASIA-PACIFIC ANTICOAGULANTS MARKET BY COUNTRY
10.1. Asia-Pacific Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Asia-Pacific Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. China
10.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.4. Japan
10.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.5. India
10.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.6. Australia
10.6.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.6.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.6.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.6.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.7. South Korea
10.7.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.7.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.7.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.7.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.8. Rest of Asia-Pacific
10.8.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.8.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.8.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.8.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
CHAPTER 11. LATIN AMERICA ANTICOAGULANTS MARKET BY COUNTRY
11.1. Latin America Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Latin America Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Brazil
11.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.4. Argentina
11.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million
11.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million))
11.5. Rest of Latin America
11.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
CHAPTER 12. MIDDLE EAST ANTICOAGULANTS MARKET BY COUNTRY
12.1. Middle East Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Middle East Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Saudi Arabia
12.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
12.4. UAE
12.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
12.5. Rest of Middle East
12.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
CHAPTER 13. AFRICA ANTICOAGULANTS MARKET BY COUNTRY
13.1. Africa Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
13.2. Africa Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. South Africa
13.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
13.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
13.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
13.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
13.4. Egypt
13.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
13.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
13.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
13.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
13.5. Rest of Africa
13.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
13.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
13.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
13.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
CHAPTER 14. COMPANY PROFILE
14.1. Bristol-Myers Squibb Company
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Product Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. Pfizer, Inc.
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Product Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. Bayer Healthcare
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Product Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. Sanofi
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Product Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Boehringer Ingelheim International GmbH
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Product Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. Johnson & Johnson Services, Inc.
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Product Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. Daiichi Sankyo Company Limited
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Product Portfolio
14.7.5. Key Developments
14.7.6. Strategies
CHAPTER 15. RESEARCH APPROACH
15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope